E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2203-2208

  Wechter, William J ^a,d   Leipold, Douglas D ^a   Murray Jr , E David ^a   Quiggle, David ^a   McCracken, John D ^b   Barrios, Robert S ^c   Greenberg, Norman M ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Encore Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; BODY WEIGHT; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLURBIPROFEN; HEMATOCRIT; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN SIZE; PROSTATIC NEOPLASMS; RATS; STEREOISOMERISM; UROGENITAL SYSTEM;

EID: 0034655083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Tang, D. C., and Porter, A. T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 32: 284-293 1997.
3. Min/+ mouse model: implications of prophylaxis and treatment of colon cancer. Cancer Res., 57: 4316-4324, 1997.
4. Riendeau, D., Charleson, S., Cromlish, W., Mancini, J. A., Wong, E., and Guay, J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol., 75: 1088-1095, 1997.
5. Tjandrawinata, R. R., Dahiya, R., and Hughes-Fulford, M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Brit. J. Cancer, 75: 1111-1118, 1997.
6. 2 in human colon cancer cells. Cancer Res., 58: 362-366, 1998.
7. Maxwell, W. J., Kelleher, D. Keating, J. J., Hogan, F. P., Bloomfield, F. J., MacDonald, G. S., and Keeling. P. W. N. Measurement of arachidonate and its metabolites extracted from normal and malignant gastrointestinal tissues. Digestion, 47: 160-166, 1990.
8. Bennett, A., Civier, A., Hensby, C. N. Melhuish, P. B., and Stamford, I. F. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut, 28: 315-318, 1987.
9. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
10. Berges, R. S., Vakanovic, J., Epsteins, J. I., Carmichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. H., and Isaacs, J. T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1: 473-480, 1995.
11. Aihara, M., Scardino, P. T., Truong, L. D., Wheeler, T. M., Goad, J. R., Yang, G., and Thompson, T. C. Frequency of apoptotic bodies correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer (Phila.), 75: 522-529, 1995.
12. Gingrich, J. R., and Greenberg, N. M. A transgenic mouse prostate cancer model. Toxicol. Pathol., 24: 502-504, 1996.
13. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., R. J. Malusik, and Rosen, J. M. Prostate cancer in a transgenic mouse. Proc. Natl. Aced. Sci. USA., 92: 3439-3443, 1995.
14. Greenberg, N. M., DeMayo, F. J., Sheppard, P. C., Barrios, R., Lebovitz, R., Finegold, M., Angelopolou, R., Dodd, J. G., Duckworth., M. L., Rosen, J. M., and Matusik, R. J. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol., 8: 8230-239, 1994.
15. Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., and Friedman, M. A. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin. Oncol., 3: 827-841, 1985.
16. Traversa, K., Walker, A. M., Ippolito, F. M., Caffari, B., Capruso, L., Dezi, A., Koch, M., Maggini, M., Alegiani, S. S., and Raschetti, R. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology, 6: 49-54, 1995.
17. Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., and Russell, R. I. Gastrointestinal damage associated with the use of non-steroidal antiinflammatory drugs. N. Engl. J. Med., 327: 749-754, 1992.
18. Weehter, W. J., McCracken, J. D., Kantoci, D., Murray, E. D., Quiggle, D. D., Leipold, D. D., Gibson, K., Mineyama, Y., and Liu, Y. Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat. Dig. Dis. Sci. 43: 1264-1274, 1998.
19. Geisslinger, G., Lotsch, J., Menzel, S., Kobal, G., and Brune, K. Stereoselective Disposition of Flurbiprofen in Healthy Subjects Following Administration of the Single Enantiomers. Br. J. Clin. Pharmacol., 37: 392-394, 1994.
20. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis, Cancer Res., 56: 456-4569, 1996.
21. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
22. Nakatsugi, S., Fukutake, M., Takahashi, M., Fukuda, K., Isoi, T., Taniguchi, Y., Sugimura, T., and Wakabayashi, K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxgenasc-2 inhibitor, in Min mice Jpn. J. Cancer Res., 88: 1117-1120, 1997.
23. Scheuren, N., Holger, B., Munster, T., Brune, K., and Pahl, A. Weak inhibitors of cyclooxygenases may exert their antinociceptive effect by modulation of transcription factors. In: Sinzinger et al. (eds.), Recent Advances in Prostaglandin, Thromboxane and Leukotriene Research, pp. 51-54. New York: Plenum Press, 1998.
24. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J. C., Najib, J., Maclouf, J., and Tedgui, A. Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature (Lond.)., 393: 790-793, 1998.
25. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., and Kliewer, S. A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 79: 81-94, 1997.
26. Kubota, T., Koshisuza, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptory (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Res., 58: 3344-3352, 1998.
27. Eltsner, E., Muller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806-8811, 1998.
28. Wang, Y., Corr, J. G., Thaler, H. T., Tao, Y., Fair, W. R., and Heston, W. D. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst., 87: 1456-1462, 1995.
29. Pour, P. M., Groot, K., Kazakoff, K., Anderson, K., and Schally, A. V. Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl)amine and testosterone. Cancer Res., 51: 4757-1761, 1991.
30. Karmali, R. A., Reichei, P., Cohen, L. A., Terano, T., Hirai, A., Tamura, Y., and Yoshida, S. The effects of dietary ω-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res., 7: 1173-1180, 1987.
31. Giovannucci, E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. C., and Willett, W. C. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst., 85: 1571-1579, 1993.